Vardenafil for the treatment of erectile dysfunction in men with diabetes

Xiaoxiong WANG.
National Journal of Andrology ; (12): 794-797, 2004.
Artículo en Zh | WPRIM | ID: wpr-267811

Documentos relacionados

  1. Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design.
  2. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
  3. Vardenafil in the Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis.
  4. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
  5. Re: Effect of Levitra on Sustenance of Erection (EROS): An Open-Label, Prospective, Multicenter, Single-Arm Study to Investigate Erection Duration Measured by Stopwatch with Flexible Dose Vardenafil Administered for 8 Weeks in Subjects with Erectile Dysfunction.
  6. Pharmacokinetics comparison of vardenafil as administered by an intranasal spray formulation vs a 10-mg oral tablet.
  7. [Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of oral dispersible tablet].
  8. Classical activation of macrophages and vardenafil.
  9. Identification of a novel vardenafil analogue in herbal product.
  10. Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects.